Selank: Research Overview of a Synthetic Anxiolytic Compound

Selank is a synthetic heptacompound developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in the 1990s. It is an analogue of the endogenous tetracompound tuftsin (Thr-Lys-Pro-Arg), with a stabilising extension that significantly increases its half-life in vivo. Selank has been the subject of extensive preclinical and clinical research in Russia and Eastern Europe, where it has been studied primarily for its effects on anxiety, cognition, and immune function.

Structure and Biochemistry

Selank's sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, giving it a molecular weight of approximately 751.9 Da. The C-terminal proline-glycine-proline extension was added to protect the tuftsin core from rapid enzymatic degradation, extending its biological half-life from minutes to several hours. Selank is water-soluble and has been administered in research settings both intranasally and subcutaneously.

Research Areas

Anxiolytic Effects and GABAergic Modulation

The most extensively documented area of Selank research concerns its anxiolytic properties. Multiple studies conducted at Russian research institutes have demonstrated that Selank reduces anxiety-related behaviour in rodent models, including elevated plus maze and open field tests, without the sedative or muscle-relaxant effects associated with benzodiazepines. A key mechanistic study by Semenova et al. (2010) published in the Bulletin of Experimental Biology and Medicine demonstrated that Selank modulates the expression of GABA-A receptor subunits in the hippocampus and frontal cortex, suggesting a GABAergic mechanism of action distinct from classical benzodiazepine binding.

Serotonin and Monoamine Neurotransmission

Research has also implicated the serotonergic system in Selank's effects. Studies in rodent models have shown that Selank increases the expression of serotonin transporter (SERT) mRNA in the raphe nuclei and modulates 5-HT turnover in limbic regions. A 2007 study by Narkevich et al. in Eksperimental'naya i Klinicheskaya Farmakologiya reported that Selank increased serotonin levels in the hippocampus and striatum of rats, with effects comparable in magnitude to those of classical SSRIs at equivalent time points.

Cognitive Enhancement and Memory

Selank has been studied for its effects on learning and memory in animal models. Research using the Morris water maze and passive avoidance paradigms has demonstrated improved acquisition and retention of spatial memory in rodents treated with Selank. The proposed mechanism involves upregulation of brain-derived neurotrophic factor (BDNF) expression, which plays a critical role in synaptic plasticity and long-term potentiation. A 2011 study by Semenova et al. reported that Selank increased BDNF mRNA expression in the hippocampus by approximately 40% compared to controls.

Immune Modulation

Selank's structural similarity to tuftsin — a naturally occurring immunomodulatory compound derived from IgG — has driven research into its effects on immune function. Studies have shown that Selank modulates the expression of interleukins, particularly IL-6 and IL-2, and influences T-cell activity. A 2008 study by Kozlovskaya et al. examined Selank's effects on cytokine profiles in patients with anxiety disorders, reporting normalisation of elevated IL-6 levels alongside anxiolytic effects. The dual immunological and neurological activity has made Selank of interest in research on the gut-brain-immune axis.

Enkephalin Metabolism

An early mechanistic study by Zozulya et al. (1999) demonstrated that Selank inhibits the enzymatic degradation of met-enkephalin, an endogenous opioid compound involved in stress regulation and pain modulation. By prolonging the half-life of enkephalins, Selank may modulate the opioid system indirectly, contributing to its anxiolytic and stress-protective effects.

Clinical Research

Selank has been studied in human subjects in Russia, where it was registered as a pharmaceutical agent (Selank nasal spray) by the Russian Ministry of Health in 2009. Clinical trials conducted at the Serbsky National Medical Research Centre examined its effects in patients with generalised anxiety disorder (GAD) and neurasthenia, reporting significant reductions in Hamilton Anxiety Scale (HAM-A) scores with a favourable tolerability profile. These trials, while limited by sample size and regional scope, provide a foundation for further investigation.

Pharmacokinetics

Selank is rapidly absorbed following intranasal administration, with peak plasma concentrations observed within 30 minutes. Its extended half-life relative to tuftsin (approximately 2–3 hours in rodent models) is attributed to the C-terminal extension. It crosses the blood-brain barrier, as evidenced by its central effects and detection in cerebrospinal fluid in animal studies. Metabolism occurs primarily via peptidase cleavage, with the resulting fragments showing no significant biological activity.

Research Specifications

Important Notice

All information presented here is intended for educational and research purposes only. Selank supplied by Compoundx is for laboratory research use and is not intended for human consumption, therapeutic use, or veterinary application. Researchers should consult relevant institutional guidelines and applicable regulations before use.

---

Compoundx supplies research-grade Selank at >99% purity, verified by HPLC and mass spectrometry. View product → [blocked]